The legacy status of Viagra, and the parent firm copyright, presents a intriguing question for shareholders . While earnings initially exploded , the impending patent expiration and growing generic rivalry https://woodyfwxm980265.bloggactivo.com/40549291/the-blue-pill-and-big-pharma-a-speculative-investment